ISSN: 1838-7640Theranostics
Global reach, higher impact
Theranostics 2019; 9(16):4595-4596. doi:10.7150/thno.36746 This issue Cite
Erratum
Site-specific stabilization of minigastrin analogs against enzymatic degradation for enhanced cholecystokinin-2 receptor targeting: Erratum
Maximilian Klingler1, Clemens Decristoforo1, Christine Rangger1, Dominik Summer1, Julie Foster2, Jane K Sosabowski2, Elisabeth von Guggenberg1 
1. Department of Nuclear Medicine, Medical University of Innsbruck, Innsbruck, Austria
2. Centre for Molecular Oncology, Barts Cancer Institute, Queen Mary University of London, London, United Kingdom
Citation:
Klingler M, Decristoforo C, Rangger C, Summer D, Foster J, Sosabowski JK, von Guggenberg E. Site-specific stabilization of minigastrin analogs against enzymatic degradation for enhanced cholecystokinin-2 receptor targeting: Erratum. Theranostics 2019; 9(16):4595-4596. doi:10.7150/thno.36746. https://www.thno.org/v09p4595.htm
Other stylesCorrected-article in Theranostics, Volume 8, 2896
In our paper [1] unfortunately an error occurred in Figure 1. We therefore would like to provide the readers with the corrected figure and apologize for this inconvenience.
Figure 1
Structure of A) DOTA-MG11, B) DOTA-MGS1, C) DOTA-MGS2, D) DOTA-MGS3, E) DOTA-MGS4; R = DOTA-DGlu-Ala-Tyr-Gly.
References
1. Klingler M, Decristoforo C, Rangger C, Summer D, Foster J, Sosabowski JK, von Guggenberg E. Site-specific stabilization of minigastrin analogs against enzymatic degradation for enhanced cholecystokinin-2 receptor targeting. Theranostics. 2018;8(11):2896-2908
Author contact
Corresponding author: E-mail: elisabeth.von-guggenbergac.at; Tel: +4351250480960; Fax: +435125046780960
Published 2019-6-19
Citation styles
APA
Klingler, M., Decristoforo, C., Rangger, C., Summer, D., Foster, J., Sosabowski, J.K., von Guggenberg, E. (2019). Site-specific stabilization of minigastrin analogs against enzymatic degradation for enhanced cholecystokinin-2 receptor targeting: Erratum. Theranostics, 9(16), 4595-4596. https://doi.org/10.7150/thno.36746.
ACS
Klingler, M.; Decristoforo, C.; Rangger, C.; Summer, D.; Foster, J.; Sosabowski, J.K.; von Guggenberg, E. Site-specific stabilization of minigastrin analogs against enzymatic degradation for enhanced cholecystokinin-2 receptor targeting: Erratum. Theranostics 2019, 9 (16), 4595-4596. DOI: 10.7150/thno.36746.
NLM
Klingler M, Decristoforo C, Rangger C, Summer D, Foster J, Sosabowski JK, von Guggenberg E. Site-specific stabilization of minigastrin analogs against enzymatic degradation for enhanced cholecystokinin-2 receptor targeting: Erratum. Theranostics 2019; 9(16):4595-4596. doi:10.7150/thno.36746. https://www.thno.org/v09p4595.htm
CSE
Klingler M, Decristoforo C, Rangger C, Summer D, Foster J, Sosabowski JK, von Guggenberg E. 2019. Site-specific stabilization of minigastrin analogs against enzymatic degradation for enhanced cholecystokinin-2 receptor targeting: Erratum. Theranostics. 9(16):4595-4596.
This is an open access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/). See http://ivyspring.com/terms for full terms and conditions.